pp-011 Tablets 80mg
Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
China
Comments
Oral, second-generation androgen receptor antagonist. Indication: Metastatic castration-resistant prostate cancer (mCRPC). Ongoing/finished trials: Phase 3 – nmCRPC, Phase 3 – mCSPC ,Phase 2/3 – high-risk localized/locally advanced prostate cancer.
Manufacturer #17216
Global developer of innovative drugs in oncology, metabolic, autoimmune, and cardiovascular diseases, with 14 in-house products and multiple partnerships. Over 5,000 R&D staff across global centers and strong IP, clinical pipeline, and high-standard manufacturing.
Manufacturer usually replies in 41 days